Systemic chemotherapy for urothelial transitional cell carcinoma: an overview of toxicity.
Chemotherapy for urothelial transitional cell carcinoma improves disease-related symptoms and overall survival. Unfortunately, many commonly used cytotoxic regimens affect normal as well as malignant tissue, resulting in toxicities that may require prompt medical diagnosis and management. This article reviews the reported toxicities of both single agent and combination chemotherapy regimens used to treat metastatic transitional cell carcinoma.
Moulder
S L
SL
Genitourinary Oncology Program, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232-6307, USA.
Roth
B J
BJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D003638:Deafness / Q000139:chemically induced; D006801:Humans; D009422:Nervous System Diseases / Q000139:chemically induced; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*